Comparative analysis of brivaracetam and levetiracetam in epilepsy treatment

• DOI: 10.4103/etmj.etmj-d-24-00027
• Publication Date: 2025-04-04T10:00:06Z
• Authors: Ming-Yuan Hsu; Shu-Wei Hu; Hueng-Chuen Fan
• Keywords: Levetiracetam

Abstract Epilepsy affects millions of people worldwide, necessitating effective and safe treatment options. Brivaracetam (BRV) levetiracetam (LEV) are antiepileptic drugs that target the synaptic vesicle protein 2A (SV2A). Despite similarities in their chemical structure, BRV LEV exhibit distinct pharmacological profiles. This study provides a detailed comparative analysis LEV, focusing on mechanisms action, preclinical profiles, pharmacokinetic pharmacodynamic properties. Clinical trial data highlight efficacy safety both drugs, with showing higher affinity for SV2A greater potency certain seizure models. Additionally, emerging strategies future directions epilepsy research discussed, highlighting potential advancing care.